SAM
SMMT icon

Shell Asset Management’s Summit Therapeutics SMMT Stock Holding History

Shell Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-94,910
Closed -$248K – 1299
2023
Q4 		$248K Sell
94,910
-222,330
-70% -$457K 0.01% 775
2023
Q3 		$593K Sell
317,240
-5,498
-2% -$10.5K 0.02% 492
2023
Q2 		$810K Buy
+322,738
New +$589K 0.03% 420

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Shell Asset Management's SMMT Position: Q1 2024 in Review

Shell Asset Management sold out of Summit Therapeutics (SMMT) in Q1 2024, closing a stake of 94,910 shares — an estimated $248K sold.

Shell Asset Management first reported a position in SMMT in Q2 2023 and held it in 3 quarters. The position peaked at $810K in Q2 2023. 105 funds tracked by Wall St. Rank hold SMMT as of Q1 2024.

  • Shell Asset Management reported no remaining Summit Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Shell Asset Management sold 94,910 Summit Therapeutics shares in Q1 2024, an estimated $248K.
  • Shell Asset Management first reported a position in Summit Therapeutics in Q2 2023 and held it in 3 quarters.
  • Shell Asset Management's Summit Therapeutics position peaked at $810K in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2024.

Based on Shell Asset Management's 13F filing for Q1 2024, filed 14 May 2024.